Hepatitis over time and in combination
The hepatitis literature gives me an awkward puzzle: an encouraging difference can fade at a later visit or disappear in the overall trial result.
Hepatitis B with cirrhosis
A systematic review of 7 randomised trials involving 1,144 people with HBV-related cirrhosis compared entecavir plus thymosin alpha-1 with entecavir alone. The combination produced a higher complete response, plus higher rates of undetectable HBV DNA and HBeAg loss at 24 weeks, while differences were not significant at 48–52 weeks. HBV DNA and HBeAg were viral markers followed in the analysis.
I dislike losing the later visit when an early difference sounds encouraging. The review gives the early result somewhere to go, and the lack of a significant difference later changes the impression. It also reported fewer adverse events with the combination.
This is a comparison of accompanying treatments in people with hepatitis B-related cirrhosis. Its particular population and follow-up periods give the finding its meaning. The result leaves me interested in the combination and cautious about how long a claimed advantage can be said to persist.
Adding it to peginterferon
A different hepatitis B study gives a less encouraging answer. In a prospective, multicentre, randomised open-label trial of 51 HBeAg-positive patients with chronic hepatitis B, short-term thymosin alpha-1 added to peginterferon alfa-2a was not superior to peginterferon alone for the combined antiviral response. Adverse events also did not differ significantly.
These studies ask different questions. The comparator and treatment setting changed. A result for thymosin alpha-1 alone in one study cannot establish the value of adding it to a different treatment in another. The practical question in the latter study was the extra contribution, and that comparison failed to establish one.
Hepatitis C: everyone assigned, everyone completing
The hepatitis C literature offers an especially awkward division. In a randomised placebo-controlled trial of 552 patients who had not responded to peginterferon plus ribavirin, adding thymosin alpha-1 did not improve sustained virological response in the intention-to-treat population: 12.7% versus 10.5%. Intention-to-treat follows the original treatment assignment, including people who did not finish.
Among those completing all 48 weeks, the same paper reported 41.0% versus 26.3%. The second comparison is tempting. Completion, however, defines a narrower group after treatment has begun. The overall trial result still has to travel with it.
I wanted these papers to offer a cleaner distinction between success and failure. Instead, the question keeps changing with the virus, the accompanying treatment and the group being analysed. That makes the hepatitis story more demanding, and more useful, than a favourable adjective can manage on its own.